Results 21 to 30 of about 2,606,163 (178)

The current state of ototoxicity monitoring in New Zealand. [PDF]

The New Zealand medical journal, 2014
To explore medical oncologists' and audiologists' knowledge and attitudes regarding ototoxicity monitoring, and to gain an understanding of monitoring currently being implemented at District Health Boards (DHBs) nationwide. We also aimed to identify ways in which audiological outcomes for patients receiving potentially ototoxic treatments could be ...
Lotte, Steffens, Kinau, Venter, Greg A, O'Beirne, Rebecca, Kelly-Campbell, David, Gibbs, Philip, Bird   +5 more
openaire   +2 more sources

Audiologic Assessment and Management of Teprotumumab-Associated Ototoxicity: An Updated Narrative Review [PDF]

Audiology Research
Introduction: Teprotumumab (Tepezza®), an insulin-like growth factor-1 receptor (IGF-1R) antagonist, is the first FDA-approved targeted therapy for thyroid eye disease (TED).
John Williams, Alex Elkins, Alp Sarigul, Mary Frances Johnson, Charles E. Bishop   +4 more
doaj   +2 more sources

Clinical Considerations of Amikacin Pharmacotherapy in Adults—A Narrative Review with Focus on Safety and TDM [PDF]

Antibiotics
Background: Amikacin remains a key agent in the treatment of severe and complicated infections due to its bactericidal activity and low risk of Clostridioides difficile infection. It retains activity against most aerobic Gram-negative bacteria, including
Daniel Orzechowski, Aleksandra Mroczkowska, Adrian Bryła, Anna Rapacz   +3 more
doaj   +2 more sources

Exploring and Overcoming Challenges for Efficient Audiological Testing in Children Under 5 Years of Age—Screening with Otoacoustic Emissions [PDF]

Audiology Research
Background/Objectives: Cisplatin-exposed pediatric cancer patients are at increased risk of ototoxicity, particularly those under 5 years of age. In this group, audiological monitoring is challenging, as interpretation of otoacoustic emissions (OAEs) and
Nienke Streefkerk, Franciscus A. Diepstraten, Evangeline A. Huis in ’t Veld, Antoinette am Zehnhoff-Dinnesen, Martine van Grotel, Katrin Neumann, Annelot J. M. Meijer, Frédéric Amant, Ross Parfitt, L’udmila Verešpejová, Penelope R. Brock, Lisa L. Hunter, Hiske W. Helleman, Beth Brooks, Kaukab M. Rajput, Kristin Knight, Marry M. van den Heuvel-Eibrink, Alexander E. Hoetink   +17 more
doaj   +2 more sources

High incidence of cisplatin-induced ototoxicity in paediatric patients in the Western Cape, South Africa [PDF]

South African Journal of Oncology, 2018
Background: Fourteen million new cancer cases are reported annually, and up to 10% of those involve children below 15 years. Cisplatin, a commonly used anti-cancer drug for its high success rate, is associated with ototoxicity.
Mukovhe Phanguphangu, Lebogang Ramma
doaj   +2 more sources

Re-telling the story of aminoglycoside ototoxicity: tales from sub-Saharan Africa [PDF]

Frontiers in Neurology
BackgroundAminoglycosides, such as Streptomycin, are cheap, potent antibiotics widely used Sub-Saharan Africa. However, aminoglycosides are the commonest cause of ototoxicity.
Adebolajo A. Adeyemo, Adebolajo A. Adeyemo, Babatunde Adedokun, Josephine Adeolu, Joshua O. Akinyemi, Olayemi O. Omotade, Odunayo M. Oluwatosin   +6 more
doaj   +2 more sources

Platinum-Induced Ototoxicity in Pediatric Cancer Patients: A Comprehensive Approach to Monitoring Strategies, Management Interventions, and Future Directions

Children
Platinum-induced ototoxicity constitutes a significant adverse effect in pediatric oncology, frequently resulting in permanent hearing impairment with profound implications for quality of life, language acquisition, and scholastic performance.
Antonio Ruggiero, Alberto Romano, Palma Maurizi, Dario Talloa, Fernando Fuccillo, Stefano Mastrangelo, Giorgio Attinà   +6 more
doaj   +3 more sources

A study of ototoxicity in adolescents and adults: Ototoxicity incidence, audiological monitoring, risk profiles and blood biomarkers

, 2023
Introduction: Nearly half of the patients who underwent chemotherapy received cisplatin as part of their regimen. Cisplatin-induced hearing loss generally starts at high frequencies first and can affect the speech frequency range after prolonged use ...
Awad, Asma Rafa. A.
core   +3 more sources

Applying U.S. National Guidelines for Ototoxicity Monitoring in Adult Patients: Perspectives on Patient Populations, Service Gaps, Barriers and Solutions [PDF]

International Journal of Audiology, 2018
Dawn Konrad-Martin, Gayla L Poling, Angie Garinis   +2 more
exaly   +2 more sources

Ototoxicity Monitoring Through the Eyes of the Treating Physician: Perspectives From Pulmonology and Medical Oncology [PDF]

International Journal of Audiology, 2018
Dawn Konrad-Martin, Angie Garinis, Kevin P Fennelly   +2 more
exaly   +2 more sources